Notably, comorbid cardiovascular risk factors [BP readings, as well as higher plasma glucose and high-density lipoprotein cholesterol (HDL-C)] were associated with disease-modifying therapy (DMT) use, particularly interferon beta and glatiramer acetate versus natalizumab [29], and the presence of hypertension was associated with changes in brain volume/lesions [30]. Here, IFNB1 is linked to hypertensive disorder.